SCHAUMBURG, Ill., Oct. 18 /PRNewswire/ — Sagent
Pharmaceuticals, Inc., a privately held specialty pharmaceutical
company, today announced the commercial launch of
ANEclear™, an easy-to-use, disposable anesthesia
recovery device at the American Society of Anesthesia (ASA) meeting
in San Diego.
Approximately 23 million surgical procedures are performed
annually in the United States involving general anesthesia using
inhaled anesthetic gases. ANEclear is the only FDA cleared
device that offers clinicians a simple method to rapidly remove
unwanted anesthetic gases from their patients’ brain, blood and
lungs at the end of the surgical procedure. ANEclear’s
patented design allows patients to partially rebreathe their own
exhaled carbon dioxide while trapping the most commonly used
volatile gases. ANEclear’s accelerated wash-out of these
volatile anesthetics provides for significantly shorter patient
anesthesia recovery times and surgical wake-ups.
“ANEclear is an important tool for anesthesia providers and
recovery room caregivers to accelerate patient emergence in both
the outpatient and inpatient setting,” said Jeffrey M. Yordon,
chief executive officer, founder and chairman of the board, Sagent
Pharmaceuticals, Inc. “The launch of this innovative device
further demonstrates Sagent’s commitment to introducing unique
solutions in response to the needs of caregivers and patients.”
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, founded in 2006, is a privately held
specialty pharmaceutical company focused on developing,
manufacturing, sourcing and marketing pharmaceutical products, with
a specific emphasis on injectable products. Sagent has
created a unique, global network of resources, comprised of rapid
development capabilities, sophisticated manufacturing and
innovative drug-delivery technologies, quickly yielding an
extensive portfolio of pharmaceutical products th
‘/>”/>
